Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14454753 | 0.80 | HTR2C (0.46) | MCHR1HTR2CALDH1A1MAPK1MAPT | |
| SCHEMBL14501781 | 0.80 | MCHR1 (0.47) | MCHR1HTR2CALDH1A1MAPK1MAPT | |
| SCHEMBL14454752 | 0.79 | HTR2C (0.46) | MCHR1HTR2CALDH1A1MAPK1MAPT | |
| SCHEMBL5582623 | 0.75 | ALOX5 (0.40) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL5377259 | 0.74 | MCHR1 (0.50) | MCHR1HTR2CACHEALDH1A1DRD2 | |
| SCHEMBL5583088 | 0.72 | MCHR1 (0.50) | MCHR1HTR2CACHEALDH1A1DRD2 | |
| Hydrochloric Acid SCHEMBL5582840 | 0.71 | MCHR1 (0.49) | MCHR1HTR2CACHEALDH1A1DRD2 | |
| SCHEMBL5582749 | 0.69 | ACHE (0.41) | ACHEALDH1A1DRD2MAOAMAPT | |
| SCHEMBL5582813 | 0.69 | MCHR1 (0.85) | MCHR1HTR2CALDH1A1LMNARAB9A | |
| SCHEMBL12440576 | 0.68 | ALOX5 (0.52) | MCHR1HTR2CALDH1A1MAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | MCHR1 433/4885HTR2C 434/4885ACHE 1222/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | MCHR1 4695/4885HTR2C 4610/4885ACHE 1689/4885 |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 195/4885ACHE 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.